Pharmsynthez Stock

LIFE

RU000A0JR514

Pharmaceuticals

End-of-day quote Moscow Micex - RTS Other stock markets 2022-07-08			5-day change	1st Jan Change
4.505 ^RUB	+10.15%		-.--%	-

06-02	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Farmsintez PAO (Farmsintez OJSC) is a Russia-based company, which is engaged in the pharmaceutical sector. The Company focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The Company sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. It has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Companyâ€™s major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
LIFE Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	1.36B 106B 1.19B 1.11B 1.02B 1.91B 131B 1.95B 13.25B 5.17B 64.05B 5.09B 4.98B 222B	P/E 2021	-2.42x	P/E 2022	-6.53x
Enterprise Value	2.09B 164B 1.84B 1.71B 1.57B 2.95B 203B 3B 20.44B 7.97B 98.83B 7.85B 7.68B 343B	EV / Sales 2021	5.43x	EV / Sales 2022	5.51x
Free-Float	95.22%	Yield 2021 *	-	Yield 2022	-

06-02	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-27	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-08-29	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2025	CI
23-09-27	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-05-18	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
23-05-18	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-11-07	Public Joint-Stock Company "Pharmsynthez" announced that it expects to receive funding from Central Bank of the Russian Federation	CI
22-04-27	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
21-11-11	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2021	CI
21-10-15	Xenetic Biosciences, Inc. Enters into Amendment Number One to Master Services Agreement with PJSC Pharmsynthez	CI
21-04-14	Market Chatter: South Korean Regulator Rejects Thelma Therapeutics's Phase Three Trial for COVID-19 Cure	MT
21-03-01	Public Joint-Stock Company Pharmsynthez Reports Earnings Results for the Full Year Ended December 31, 2018	CI

5 years	2.64		7
10 years	2.64		18.75

Manager	Title	Age	Since
Petr Vladimirovich Kruglyakov CEO	Chief Executive Officer	48	2013-12-31
Alexey Shafranov DFI	Director of Finance/CFO	47	-
Dmitriy Nikolayevich Poznyak CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dmitriy Genkin CHM	Chairman	57	2004-12-31
Indrek Kasela BRD	Director/Board Member	54	2006-12-31
Steve Gorelik BRD	Director/Board Member	47	2006-12-31

Pharmsynthez Stock

Stocks

LIFE

RU000A0JR514

Pharmaceuticals

Valuation: Pharmsynthez

Latest news : Pharmsynthez

Quotes and Performance

Course Extremes

Managers and Directors: Pharmsynthez

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHARMSYNTHEZ	+10.15%	-.--%	-.--%	-.--%	25.27M
ELI LILLY AND COMPANY	+1.97%	+1.43%	+48.44%	+158.18%	1,037B
JOHNSON & JOHNSON	+1.42%	+3.72%	+53.32%	+51.55%	615B
ABBVIE INC.	+1.43%	+0.99%	+34.83%	+79.44%	448B
ROCHE HOLDING AG	+5.14%	+5.84%	+37.54%	+27.28%	326B
NOVARTIS AG	+1.85%	+4.64%	+38.53%	+39.87%	293B
ASTRAZENECA PLC	-0.11%	+0.97%	+22.57%	+17.81%	264B
NOVO NORDISK A/S	+0.25%	-3.10%	-24.44%	-42.25%	216B
AMGEN INC.	+1.49%	-0.02%	+20.14%	+57.80%	198B
GILEAD SCIENCES, INC.	+0.40%	-3.99%	+15.23%	+68.50%	162B
Average	+2.40%	+2.02%	+24.62%	+45.82%	355.75B
Weighted average by Cap.	+1.65%	+1.47%	+36.34%	+75.89%

	2021	2022
Net sales	438M 34.39B 386M 358M 329M 618M 42.45B 629M 4.28B 1.67B 20.7B 1.65B 1.61B 71.83B	380M 29.79B 334M 310M 285M 535M 36.77B 545M 3.71B 1.45B 17.93B 1.43B 1.39B 62.22B
Net income	-698M -54.72B -613M -570M -524M -983M -67.55B -1B -6.82B -2.66B -32.95B -2.62B -2.56B -114B	-207M -16.28B -182M -170M -156M -292M -20.09B -298M -2.03B -791M -9.8B -779M -762M -34B
Net Debt	693M 54.36B 609M 566M 521M 976M 67.1B 994M 6.77B 2.64B 32.73B 2.6B 2.55B 114B	736M 57.76B 648M 602M 553M 1.04B 71.3B 1.06B 7.19B 2.81B 34.78B 2.76B 2.7B 121B